Skip to main content

Revelation Biosciences, Inc.

corporate_fare Company Profile

Revelation Biosciences, Inc.

REVB·NASDAQ·Life Sciences·CIK 0001810560

Revelation is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company has multiple ongoing programs to evaluate Gemini, including GEM-AKI as a treatment for acute kidney injury (AKI) and GEM-CKD as a treatment for chronic kidney disease (CKD). Revelation was incorporated in Delaware on November 20, 2019, originally as Petra Acquisition, Inc., and is based in San Diego, California. Its common stock and Public Warrants are listed on The Nasdaq Stock Market, LLC (Nasdaq) under the ticker symbols "REVB" and "REVBW," respectively. On June 23, 2025, stockholders granted discretionary authority to the board of directors to amend the certificate of incorporation for reverse stock splits. Following this, a 1-for-3 reverse stock split of outstanding common stock became effective on July 7, 2025. Additionally, a 1-for-4 reverse stock split of outstanding common stock became effective on January 28, 2026.

Revelation Biosciences, Inc. (NASDAQ:REVB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for REVB at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Revelation Biosciences Registers 4.27M Shares for Resale, Signaling Massive Potential Dilution
  • Revelation Biosciences Secures $7.3M from Warrant Exercises, Issues New Warrants
  • Revelation Biosciences Secures FDA Agreement for Gemini AKI Approval Pathway

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$8.91M
Diluted EPS
-$23.95
Op. Cash Flow
-$8.27M
Operating Income
-$9.07M
Cash & Equivalents
$10.7M
Debt / Equity
0.00×
Shares Outstanding
1.58M sh
Source: 10-K · filed 2026-02-26 · accession 0001193125-26-076552
$3.55 -3.79% today
52-week range · as of 2026-11-05 $3.08 – $40.6
Market cap
$2.39M
Volume
9.8K (0.5× avg)
3-mo avg 20.8K
Live data · 2026-11-22 12:35 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed REVB - Filings & News (Page 2)

REVB
Jan 30, 2026, 4:05 PM EST
Filing Type: S-3
Importance Score:
9
Price at Filing: $2.03
Real-time Price: $3.55 info
Change: Reverse Stock Split info
Market Cap: $2.392M info
REVB
Jan 28, 2026, 6:46 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.03
Real-time Price: $3.55 info
Change: Reverse Stock Split info
Market Cap: $2.392M info
REVB
Jan 21, 2026, 7:01 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.8331
Real-time Price: $3.55 info
Change: Reverse Stock Split info
Market Cap: $2.392M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets